Satoshi Kubo

7.0k total citations
157 papers, 3.0k citations indexed

About

Satoshi Kubo is a scholar working on Rheumatology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Satoshi Kubo has authored 157 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Rheumatology, 48 papers in Immunology and 32 papers in Pathology and Forensic Medicine. Recurrent topics in Satoshi Kubo's work include Rheumatoid Arthritis Research and Therapies (43 papers), Systemic Lupus Erythematosus Research (41 papers) and Chronic Lymphocytic Leukemia Research (19 papers). Satoshi Kubo is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (43 papers), Systemic Lupus Erythematosus Research (41 papers) and Chronic Lymphocytic Leukemia Research (19 papers). Satoshi Kubo collaborates with scholars based in Japan, Germany and Italy. Satoshi Kubo's co-authors include Yoshiya Tanaka, Shingo Nakayamada, Kazuhisa Nakano, S. Iwata, Kazuyoshi Saito, Kunihiro Yamaoka, Yusuke Miyazaki, Ippei Miyagawa, Maiko Yoshikawa and Kentaro Hanami and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and The Journal of Immunology.

In The Last Decade

Satoshi Kubo

143 papers receiving 3.0k citations

Peers

Countries citing papers authored by Satoshi Kubo

Since Specialization

Citations

This map shows the geographic impact of Satoshi Kubo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Kubo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Kubo more than expected).

Fields of papers citing papers by Satoshi Kubo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoshi Kubo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Kubo. The network helps show where Satoshi Kubo may publish in the future.

Co-authorship network of co-authors of Satoshi Kubo

This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Kubo. A scholar is included among the top collaborators of Satoshi Kubo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Kubo. Satoshi Kubo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association of peripheral CD8⁺ T cell activation with disease activity and treatment resistance in systemic lupus erythematosus 2025 ·RMD Open ·(unknown), Shingo Nakayamada, Satoshi Kubo, Yusuke Miyazaki, Koshiro Sonomoto, Hiroaki Tanaka, Yoshiya Tanaka	1
2	Regulation of fibronectin and collagens type I, III and VI by TNF-α, TGF-β, IL-13, and tofacitinib 2025 ·Scientific Reports ·(unknown), (unknown), Anne‐Christine Bay‐Jensen, Peder Frederiksen, M.A. Karsdal, Bent Deleuran, Tue Wenzel Kragstrup, Satoshi Kubo, Yoshiya Tanaka, Joachim Høg Mortensen	7
3	Pursuing Precision Medicine in Managing Rheumatoid Arthritis 2025 ·International Journal of Rheumatic Diseases ·Satoshi Kubo, Yoshiya Tanaka	2
4	Predictors of the effectiveness of first-line CTLA4-Ig in patients with RA: the FIRST registry 2024 ·Lara D. Veeken ·Hiroki Kobayashi, Yusuke Miyazaki, Shingo Nakayamada, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Ayako Yamaguchi, Yoshino Inoue, Yasuyuki Todoroki, (unknown), (unknown), Yoshihisa Fujino, Shintaro Hirata, Yoshiya Tanaka	1
5	Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry 2024 ·Lara D. Veeken ·H. Sakai, Yusuke Miyazaki, Shingo Nakayamada, Satoshi Kubo, Kentaro Hanami, Shunsuke Fukuyo, Ayako Yamaguchi, Ippei Miyagawa, (unknown), (unknown), Yasuyuki Todoroki, Naoaki Ohkubo, (unknown), (unknown), Yoshiya Tanaka	1
6	Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus 2024 ·RMD Open ·(unknown), S. Iwata, Kaoru Yamagata, Yasuyuki Todoroki, Koshiro Sonomoto, Atsushi Nagayasu, Ippei Miyagawa, Satoshi Kubo, Yusuke Miyazaki, (unknown), (unknown), (unknown), Shingo Nakayamada, Yoshiya Tanaka	1
7	Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness 2024 ·Annals of the Rheumatic Diseases ·Satoshi Kubo, Yusuke Miyazaki, T Nishino, (unknown), (unknown), (unknown), Kazuyoshi Ishigaki, (unknown), Hiroaki Tanaka, (unknown), (unknown), Yoshino Inoue, Yasuyuki Todoroki, Ippei Miyagawa, Kentaro Hanami, Shingo Nakayamada, Yoshiya Tanaka	8
8	Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in mixed connective tissue disease 2023 ·Lara D. Veeken ·Yasuyuki Todoroki, Minoru Satoh, Satoshi Kubo, (unknown), Shunsuke Fukuyo, (unknown), Kazuyoshi Saito, Shin Tanaka, Shingo Nakayamada, Yoshiya Tanaka	2
9	Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry 2023 ·Lara D. Veeken ·Yusuke Miyazaki, (unknown), Shingo Nakayamada, Koshiro Sonomoto, Hiroaki Tanaka, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Ayako Yamaguchi, Ippei Miyagawa, Yasuyuki Todoroki, Masanobu Ueno, Yoshiya Tanaka	8
10	Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping 2023 ·Annals of the Rheumatic Diseases ·Hiroaki Tanaka, Yukinori Okada, Shingo Nakayamada, Yusuke Miyazaki, Kyuto Sonehara, Shinichi Namba, Suguru Honda, Yuya Shirai, Kenichi Yamamoto, Satoshi Kubo, Katsunori Ikari, Masayoshi Harigai, Koshiro Sonomoto, Yoshiya Tanaka	9
11	Early B cell factor 4 modulates FAS-mediated apoptosis and promotes cytotoxic function in human immune cells 2022 ·Proceedings of the National Academy of Sciences ·Satoshi Kubo, (unknown), Yikun Yao, (unknown), Lixin Zheng, Tovah E. Markowitz, Waipan Chan, Jian Song, Arun K. Boddapati, Keita Saeki, Björn Häupl, Ann Y. Park, Yan Cheng, Jing Cui, Thomas Oellerich, Michael J. Lenardo	10
12	Comprehensive immunophenotypic analysis reveals the pathological involvement of Th17 cells in Graves' disease 2022 ·Scientific Reports ·Keiichi Torimoto, Yosuke Okada, Shingo Nakayamada, Satoshi Kubo, Akira Kurozumi, Manabu Narisawa, Yoshiya Tanaka	15
13	Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis 2021 ·Arthritis Research & Therapy ·Masanobu Ueno, Ippei Miyagawa, Kazuhisa Nakano, S. Iwata, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Yusuke Miyazaki, (unknown), (unknown), Shingo Nakayamada, Yoshiya Tanaka	25
14	The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus 2020 ·International Journal of Rheumatic Diseases ·Ippei Miyagawa, Kazuhisa Nakano, Shingo Nakayamada, S. Iwata, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, (unknown), Yusuke Miyazaki, Yoshino Inoue, Masanobu Ueno, Naoaki Ohkubo, (unknown), Yoshiya Tanaka	10
15	Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability 2020 ·Bone ·Manabu Narisawa, Satoshi Kubo, Yosuke Okada, Kaoru Yamagata, Shingo Nakayamada, Kei Sakata, Kunihiro Yamaoka, Yoshiya Tanaka	27
16	Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus 2018 ·International Journal of Rheumatic Diseases ·Ippei Miyagawa, Kazuhisa Nakano, Shingo Nakayamada, S. Iwata, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Yoshino Inoue, Masanobu Ueno, Yoshiya Tanaka	15
17	Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study. 2017 ·PubMed ·Satoshi Kubo, Kazuhisa Nakano, Shingo Nakayamada, Shintaro Hirata, Shunsuke Fukuyo, Norifumi Sawamukai, Kazuyoshi Saito, Yoshiya Tanaka	6
18	Glioblastoma with ovarian teratoma having N-methyl-D-aspartate receptor (NMDAR) antibody in CSF—A case report 2013 ·Rinsho Shinkeigaku ·Hiroki Fujii, Satoshi Kubo, Taijun Yunoki, (unknown), Kazuhiro Takamatsu, Keiko Tanaka, Yukitoshi Takahashi, Masaru Kuriyama	4
19	Stent placement for intracranial arterial stenosis using balloon-mounted stent 2010 ·Nosotchu ·Hiroshi Tenjin, (unknown), (unknown), (unknown), (unknown), Satoshi Kubo, Yasumasa Yamamoto	1
20	Studies on the relationship between hepatic and splenic density change in dynamic CT in the presence of a large splenorenal shunt in patients with liver cirrhosis. 1993 ·PubMed ·Shigeki Sugano, Yuichi Yamazaki, (unknown), Satoshi Kubo, Yasukiyo Sumino, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact